Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Berry-Kravis, Elizabeth, Des Portes, Vincent, Hagerman, Randi, Jacquemont, Sébastien, Charles, Perrine, Visootsak, Jeannie, Brinkman, Marc, Rerat, Karin, Koumaras, Barbara, Zhu, Liansheng, Barth, Gottfried Maria, Jaecklin, Thomas, Apostol, George, von Raison, Florian·2016·Science Translational Medicine

Abstract

In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aab4109

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 35 references

Research works printed but not linked: 3

  1. 10.1002/(SICI)1098-2779(1996)2:2<96::AID-MRDD7>3.0.CO;2-V · doi:10.1002/(sici)1098-2779(1996)2:2<96::aid-mrdd7>3.0.co;2-v
  2. W. Guy in ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health Psychopharmacology Research Branch Mental Health Administration Rockville MD 1976) pp. 217–222.
  3. 10.1176/jnp.12.2.233 · DOI · Paper page

Cited by

See all 282

Metadata

Authors
Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F.
Affiliations
  • Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
  • National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
  • University of California Davis Medical Center (US)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Emory University (US)
  • Novartis (Germany) (DE)
  • Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
  • Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
  • Novartis (United States) (US)
  • Universitätsklinikum Tübingen (DE)
  • Novartis (Switzerland) (CH)
  • Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
Venue
Science Translational Medicine
Published
2016-01-13
Volume
8
Issue
321
Pages
321ra5-321ra5
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2237631658
Cited by
270
References
35
Citations by year
2026: 12 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 23 · 2021: 21 · 2020: 35 · 2019: 29 · 2018: 27 · 2017: 54 · 2016: 22
FWCI
29.74
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novartis Pharma AG
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
fragile X syndrome, metabotropic glutamate receptor 5, mGluR5 antagonist, intellectual disability, autism spectrum disorder, behavioral symptoms, synaptic plasticity, drug safety and efficacy
MeSH terms
Adolescent, Adult, Age Factors, Behavior, Cognition, Demography, Double-Blind Method, Female, Fragile X Syndrome, Humans, Indoles, Male, Placebos, Least-Squares Analysis, Treatment Outcome, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. https://app.cochat.ai/papers/10.1126/scitranslmed.aab4109
The paper
Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F. (2016). Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aab4109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.